Aim: In frozen-thawed embryo transfers (FET), Gonadotropin-Releasing Hormone (GnRH) agonists have recently been used to improve implantation results. It is preferred to administer it in the luteal phase of the previous cycle. The objective was to compare the effects of different administration days of depot GnRH agonists on implantation and pregnancy rates in the artificial cycle of FET.
Material and Methods: A retrospective case-control study was conducted in an in vitro fertilization (IVF) center in a university hospital including all women starting an artificial cycle of FET. One thousand two hundred and twenty-seven (n:1227) FET cycles were scanned from the files from October 2014 to December 2021. Depot agonists (Lucrin depot 3.75 mg sc Abbott USA.-leuprolide acetate) were used in 219 patients with endometriosis. In 58 patients it was administered at day 21 on the previous cycle (Group 1) and on 161 patients it was administered at day 2 of the same cycle (Group 2).
Results: This study showed no statistically significant difference between the two groups in laboratory parameters and endometrial thickness (p>0.05). There was not a statistically significant association between the abort rate and transfer day (p>0.05). There was not a statistically significant association between the pregnancy results and transfer day (p>0.05). The ongoing pregnancy rate (OPR) rate was relatively high in the second group compared to the twenty-first day of the previous cycle (87/161(54%) vs. 30/58 (51.7%)). The biochemical pregnancy was relatively high in the second-day group compared to the twenty-first day of the previous cycle (62/161(38.5%) vs. 21/58 (36.2%)). The abort rate was relatively high in the twenty-first-day group compared to the second-day of the cycle (25/87(28.75%) vs. 9/30(30%)).
Conclusion: In conclusion, the impacts of various administration days of depot Gonadotropin-releasing hormone (GnRH) agonists on implantation and pregnancy rates were not statistically significant.
Assisted reproduction technology; Frozen-thawed embryo transfer cycle; GnRH agonists; Implantation Assisted reproduction technology FET cycle GnRH agonist implantation
Aim: In frozen-thawed embryo transfers (FET), Gonadotropin-Releasing Hormone (GnRH) agonists have recently been used to improve implantation results. It is preferred to administer it in the luteal phase of the previous cycle. The objective was to compare the effects of different administration days of depot GnRH agonists on implantation and pregnancy rates in the artificial cycle of FET.
Material and Method: A retrospective case-control study was conducted in an in vitro fertilization (IVF) center in a university hospital, including all women starting an artificial cycle of FET. One thousand two hundred and twenty-seven (n:1227) FET cycles were scanned from the files from October 2014 to December 2021. Depot agonists (Lucrin depot 3.75 mg sc Abbott USA.-leuprolide acetate) were used in 219 patients with endometriosis. In 58 patients, it was administered on day 21 of the previous cycle (Group 1), and in 161 patients, it was administered on day 2 of the same cycle (Group 2).
Results: This study showed no statistically significant difference between the two groups in laboratory parameters and endometrial thickness (p>0.05). There was no statistically significant association between the abort rate and transfer day (p>0.05). There was no statistically significant association between the pregnancy results and transfer day (p>0.05). The ongoing pregnancy rate (OPR) rate was relatively high in the second group compared to the twenty-first day of the previous cycle (87/161(54%) vs. 30/58 (51.7%)). The biochemical pregnancy was relatively high in the second-day group compared to the twenty-first day of the previous cycle (62/161(38.5%) vs. 21/58 (36.2%)). The abort rate was relatively high in the twenty-first-day group compared to the second day of the cycle (25/87(28.75%) vs. 9/30(30%)).
Conclusion: In conclusion, the impacts of various administration days of depot Gonadotropin-releasing hormone (GnRH) agonists on implantation and pregnancy rates were not statistically significant.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Research Articles [en] Araştırma Makaleleri [tr] |
Authors | |
Publication Date | March 27, 2023 |
Published in Issue | Year 2023 |
Dergimiz; TR-Dizin ULAKBİM, ICI World of Journal's, Index Copernicus, Directory of Research Journals Indexing (DRJI), General Impact Factor, Google Scholar, Researchgate, WorldCat (OCLC), CrossRef (DOI), ROAD, ASOS İndeks, Türk Medline İndeks, Eurasian Scientific Journal Index (ESJI) ve Türkiye Atıf Dizini'nde indekslenmektedir.
EBSCO, DOAJ, OAJI, ProQuest dizinlerine müracaat yapılmış olup, değerlendirme aşamasındadır.
Makaleler "Çift-Kör Hakem Değerlendirmesi”nden geçmektedir.
Üniversitelerarası Kurul (ÜAK) Eşdeğerliği: Ulakbim TR Dizin'de olan dergilerde yayımlanan makale [10 PUAN] ve 1a, b, c hariç uluslararası indekslerde (1d) olan dergilerde yayımlanan makale [5 PUAN].
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. About predatory/questionable journals and journal charge policy
Not: Dergimiz WOS indeksli değildir ve bu nedenle Q sınıflamasına dahil değildir.
Yağmacı/şüpheli dergilerle ilgili Yüksek Öğretim Kurumu (YÖK) kararları ve yazar açıklama metni ile dergi ücret politikası: Yağmacı/Şaibeli Dergiler ve Dergi Ücret Politikası